生物标志物
医学
宫颈癌
内科学
肿瘤科
液体活检
活检
数字聚合酶链反应
癌症
胎儿游离DNA
预测值
病理
聚合酶链反应
胃肠病学
生物
基因
遗传学
怀孕
生物化学
胎儿
产前诊断
作者
Lars Sivars,Cecilia Jylhä,Ylva Crona Guterstam,Mark Zupancic,Bengt Lindqvist,Magnus Nordenskjöld,Emma Tham,Kristina Hellman
标识
DOI:10.1158/1078-0432.ccr-23-3941
摘要
Abstract Purpose: Human papillomavirus (HPV) is the cause of the majority of cervical cancers and has been showed to be released as cell-free tumour DNA (ctHPV DNA) into the circulation. We here analyse if ctHPV DNA could be used as a prognostic biomarker and/or to detect relapse earlier than traditional methods in locally advanced cervical cancer (LACC). Experimental Design: 74 patients with LACC were included, 66/74 were positive for 13 high-risk HPV-types using a bead-based assay on tumour biopsies. HPV-type-specific droplet digital PCR (ddPCR) assays were developed. Longitudinal plasma samples were then analysed for the biopsy-verified HPV-type for each patient. 418 plasma samples were analysed. Patients were followed for a median of 37 months. Results were correlated to tumour- and clinical characteristics. Results: 92.4% of pre-treatment plasma samples were positive for ctHPV DNA. Persistent ctHPV DNA in end-of-treatment, early follow-up (1-2 months after end-of-treatment) or tumour evaluation (3-4 months after end-of-treatment) plasma was correlated with worse progression-free survival (p < 0.001) compared to if ctHPV DNA was not found. The positive predictive value of ctHPV-status at early follow-up for predicting disease progression was 87.5% and the negative predictive value was 89.3%. ctHPV DNA was found in plasma before relapse was diagnosed on radiology in all patients (n=10) who experienced relapse after complete clinical response to treatment with a median 315 days lead time. Conclusions: ctHPV DNA in follow-up plasma is a promising prognostic biomarker in patients with LACC, useful for analysis of response to therapy and for early detection of relapse.
科研通智能强力驱动
Strongly Powered by AbleSci AI